A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Anupamjeet Kaur Sekhon; Aniruddha Gollapalli; Dharamjeet Kaur; Bryan Janssen; Mark L. Stevens; Fernando Valerio; Miguel A. Sierra-Hoffman

doi:10.12659/AJCR.932961

26 November 2021 : Case report USA

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Unusual or unexpected effect of treatment

Anupamjeet Kaur Sekhon^1BDEF*, Aniruddha Gollapalli^1E, Dharamjeet Kaur^2E, Bryan Janssen^3D, Mark L. Stevens

^2E, Fernando Valerio^4AE, Miguel A. Sierra-Hoffman^2E

DOI: 10.12659/AJCR.932961

Am J Case Rep 2021; 22:e932961

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 1. Liver histology pretreatment with PCSK9 inhibitor in 2019 showing (A) ballooning degeneration of hepatocytes and (B) Mallory hyaline, which is a characteristic of cytoplasmic hyaline inclusion in hepatocytes and thus resemble a peculiar manifestation of liver cell injury. (Hematoxylineosin staining, original magnification ×200).

Back to the Article

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Your Privacy